Université Clermont Auvergne, Centre Jean Perrin, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
Université Clermont Auvergne, Centre Jean Perrin, Inserm, Imagerie Moléculaire et Stratégies Théranostiques, Clermont Ferrand, France.
Clin Breast Cancer. 2018 Oct;18(5):e1093-e1102. doi: 10.1016/j.clbc.2018.06.010. Epub 2018 Jun 18.
Weight changes during adjuvant treatment for early-stage breast cancer has been associated with a poor prognosis. The long-term evolution of body composition during adjuvant treatment for breast cancer, in particular, endocrine therapy, is not well known, and new data on this topic are required. The present study assessed the evolution of weight and body composition among 33 postmenopausal breast cancer patients receiving endocrine therapy after standard adjuvant chemotherapy that included taxanes.
Dual-energy x-ray absorptiometry was used to measure the fat and lean body mass. Body water was assessed using multifrequency bioelectrical impedance analysis. The Hospital Anxiety and Depression questionnaire and the short version of the International Physical Activity Questionnaire were also administered.
During endocrine therapy, 5 of the 33 patients (15.2%) lost weight and 12 (36.4%) gained weight. The overall average gain was 2.0 ± 5.5 kg (P = .04). During this period, the fat mass, lean body mass, and body water increased. The factors linked to fat mass gain included an excess fat mass (≥ 36%) before treatment and weight loss during chemotherapy. In the overall period of adjuvant cancer treatment, 30% of the population gained > 5% of their initial weight. The average gain was the same as that during the endocrine therapy period (2.0 ± 5.4 kg; P = .031) and was characterized by an increase in total lean body mass, mainly localized in the trunk region.
Endocrine therapy appears as a pivotal period in weight and body composition management. Overfat and obese patients and those who lose weight during chemotherapy were more subject to weight and fat mass gain during endocrine therapy.
辅助治疗早期乳腺癌期间的体重变化与预后不良有关。乳腺癌辅助治疗期间，特别是内分泌治疗期间，身体成分的长期变化尚不清楚，需要这方面的新数据。本研究评估了 33 例接受紫杉烷类标准辅助化疗后接受内分泌治疗的绝经后乳腺癌患者的体重和身体成分的变化。
使用双能 X 射线吸收法测量脂肪和瘦体重。使用多频生物电阻抗分析评估身体水分。还进行了医院焦虑和抑郁问卷和国际体力活动问卷短版的评估。
在内分泌治疗期间，33 例患者中有 5 例（15.2%）体重减轻，12 例（36.4%）体重增加。总体平均增加 2.0 ± 5.5 公斤（P =.04）。在此期间，脂肪量、瘦体重和身体水分增加。与脂肪量增加相关的因素包括治疗前脂肪量过多（≥ 36%）和化疗期间体重减轻。在辅助癌症治疗的整个期间，有 30%的人群体重增加超过初始体重的 5%。平均增加量与内分泌治疗期间相同（2.0 ± 5.4 公斤；P =.031），表现为总瘦体重增加，主要集中在躯干区域。
内分泌治疗似乎是体重和身体成分管理的关键时期。超胖和肥胖患者以及化疗期间体重减轻的患者在内分泌治疗期间更容易出现体重和体脂肪增加。
